Idera Pharmaceuticals (IDRA) Stock Analysis

What Idera Pharmaceuticals does

Idera Pharmaceuticals, Inc. is a biopharmaceutical company committed to the research, development, and commercialization of medicines addressing rare diseases within the United States. A key offering is Tilsotolimod (IMO-2125), a proprietary synthetic phosphorothioate oligonucleotide. This compound functions as a direct TLR9 agonist, designed to stimulate the immune system to combat solid tumors, specifically targeting head and neck squamous cell carcinoma and colorectal cancer. The firm also holds a strategic collaboration agreement with Bristol-Myers Squibb. Founded in 1989, Idera Pharmaceuticals, Inc. is headquartered in Exton, Pennsylvania.

Key metrics

ETFs linked to IDRA

Broad-market and Healthcare sector ETFs an investor holding Idera Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how IDRA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Idera Pharmaceuticals?

Idera Pharmaceuticals trades under the ticker IDRA on NASDAQ.

Which exchange is IDRA listed on?

IDRA is listed on NASDAQ.

What sector does Idera Pharmaceuticals operate in?

Idera Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze IDRA in a portfolio?

PortView shows IDRA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.